Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

novatech s.a. z.i. athélia iii, voie antiope f-13705 la ciotat cedex francúzsko -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

novatech s.a. z.i. athélia iii, voie antiope f-13705 la ciotat cedex francúzsko -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

stada arzneimittel ag, nemecko - agomelatín - 30 - antidepressiva

Európska únia - slovenčina - EMA (European Medicines Agency)

dopharma research b.v. - meloxicam - oxicams - pigs; calves - cattlefor použitie v akútne respiračné infekcie s príslušnými liečba antibiotikami, na zníženie klinických príznakov v chove hovädzieho dobytka. na použitie pri hnačke v kombinácii s perorálnou rehydratáciou na zníženie klinických príznakov u teliat starších ako jeden týždeň a mladých, dojčiacich zvierat. pre doplnkovú liečbu pri liečbe akútnej mastitídy v kombinácii s antibiotickou liečbou. pigsfor použitie v noninfectious pohybového ústrojenstva s cieľom znížiť príznaky lameness a zápal. na zmiernenie pooperačnej bolesti spojené s menším chirurgickým zákrokom v oblasti mäkkých tkanív, ako je kastrácia. pre adjunctive terapie v liečbe puerperal septikémiu a toxaemia (mastitis-metritis-agalaktia syndróm) s vhodnej antibiotickej terapie. horsesfor použiť na zmiernenie zápalu a zmiernenie bolesti akútne a chronické ochorenia pohybového aparátu. na úľavu od bolesti spojenej s kolikou koní.

Slovensko - slovenčina - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

dopharma research b.v., holandsko - inj.

Slovensko - slovenčina - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

dopharma research b.v., holandsko - plv.sol.

Slovensko - slovenčina - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

dopharma research b.v., holandsko - inj.

Slovensko - slovenčina - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

dopharma research b.v., holandsko - inj.

Európska únia - slovenčina - EMA (European Medicines Agency)

mabxience research sl - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastické činidlá - alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with alymsys in combination with capecitabine. alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Slovensko - slovenčina - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

dopharma research b.v., holandsko - plv.sol.